Benign Prostatic Hyperplasia Treatment Market to Reach US$ 47.17 Billion by 2032 | Abbott Laboratories; Allergan Plc.; Astellas Pharma Inc.; Asahi Kasei Corporation

The global Benign Prostatic Hyperplasia (BPH) Treatment Market, valued at US$ 27.7 billion in 2021, is projected to reach US$ 47.17 billion by 2032, driven by a steady CAGR of 5%. Fueled by the rising prevalence of BPH, growing preference for minimally invasive surgeries, and advancements in drug and device therapies, this market is critical for addressing lower urinary tract symptoms in aging men. This press release explores the key drivers, projections, and opportunities shaping this vital healthcare industry.

Browse for Full Report: https://www.factmr.com/report/4412/benign-prostatic-hyperplasia-treatment-market

Why Is the Market Growing?

The increasing prevalence of BPH, affecting 50% of men aged 51-60 and 90% by age 85, drives demand for treatments like alpha blockers, 5-ARIs, and minimally invasive procedures, with 30 million men globally experiencing BPH symptoms. The shift toward minimally invasive surgeries, such as UroLift's 2020 Advanced Tissue Control System, reduces recovery time by 20% compared to traditional methods.

Innovations like Olympus's 2024 iTind device improve symptom relief by 15%. Government healthcare investments, like the U.S.'s US$ 2 billion NIH budget for urology in 2024, support growth, though high treatment costs, averaging US$ 3,000 annually for drugs, are mitigated by generics following 2024 patent expirations of drugs like Avodart.

What Are the Key Market Projections?

The market is set to create a US$ 19.47 billion opportunity by 2032, growing from US$ 27.7 billion in 2021 to US$ 47.17 billion at a 5% CAGR. The minimally invasive surgery segment, projected to surpass drug classes, grows at a 5.5% CAGR, creating a US$ 8 billion opportunity. North America, holding a 35% share in 2021, leads with a 4.9% CAGR, while Asia-Pacific grows fastest at a 7.3% CAGR, driven by medical tourism in China and India.

Historical growth from 2017 to 2021 was at a 3.8% CAGR, indicating an accelerating trend. Short-term growth (2022-2026) focuses on surgical innovations, while long-term trends (2027-2032) emphasize generics and homeopathy remedies.

Want a Sample Before Buying? Download Free Sample: https://www.factmr.com/connectus/sample?flag=S&rep_id=4412

How Can Stakeholders Leverage Opportunities?

Stakeholders in pharmaceuticals, medical devices, and healthcare can capitalize by investing in minimally invasive technologies, like Boston Scientific's 2024 Rezum system for water vapor therapy. Partnerships, such as PHAREX's 2021 collaboration with the Philippine Urological Association, enhance distribution. Targeting Asia-Pacific, with a projected US$ 17 billion market by 2030, and North

America offers significant potential. Hospital and clinic sales, accounting for 60% of revenue in 2021, ensure scalability. Compliance with FDA and CE standards boosts market trust and competitiveness.

What Does the Report Cover?

Fact.MR's report combines primary research across 30+ countries and secondary analysis, covering segments by drug class (alpha blockers, 5-alpha-reductase inhibitors, phosphodiesterase-5 inhibitors), treatment type (minimally invasive surgeries, laser therapy, others), and region (North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East & Africa). It highlights trends like minimally invasive procedures, generic drugs, and natural remedies, providing actionable insights for stakeholders.

Who Are the Market Leaders?

Key players include Abbott Laboratories, Allergan plc, Astellas Pharma, Inc., Boston Scientific Corporation, and Olympus Corporation. Astellas Pharma's 2020 Flivas approval in China expanded its dysuria treatment portfolio, while UroLift's 2020 ATC System gained traction in minimally invasive procedures. These companies, holding over 45% of the market, drive innovation through R&D and partnerships with hospitals and urological associations.

What Are the Latest Market Developments?

In 2024, minimally invasive BPH procedures grew by 10%, driven by devices like Teleflex's UroLift, reducing complications by 15%. North America's 35% share reflects high healthcare spending, while Asia-Pacific's 7.3% CAGR is fueled by medical tourism and R&D, with Japan's Olympus leading innovations. Regulatory advancements, like the FDA's 2024 approval of Silodosin generics, increased affordability by 20%. Developments such as Asahi Kasei's 2024 naftopidil formulations improved treatment efficacy, supporting market expansion.

What Challenges and Solutions Exist?

High treatment costs, averaging US$ 3,000 annually for drugs, and side effects, like those from alpha blockers affecting 10% of patients, pose challenges. Patent expirations of drugs in 2024 create opportunities for generics but reduce branded drug revenue. Solutions include low-cost biosimilars, cutting costs by 20%, and minimally invasive devices, like Endo International's 2024 laser therapies, reducing side effects. Localized production in Asia-Pacific, adopted by 15% of manufacturers, mitigates supply chain risks. Compliance with ISO 13485 and EMA standards ensures market resilience and patient confidence.

Conclusion:

The Global Benign Prostatic Hyperplasia Treatment Market is set to reach US$ 47.17 billion by 2032, driven by a 5% CAGR. With applications in drug therapies and minimally invasive surgeries, and supported by innovations in devices and generics, the market offers transformative opportunities. Stakeholders can leverage Fact.MR's insights to target high-growth regions like Asia-Pacific and North America, invest in advanced solutions, and address cost and side-effect challenges to thrive in this critical healthcare industry.

Check out More Related Studies Published by Fact.MR Research:

Psychotic Disorder Treatment Market: https://www.factmr.com/report/568/psychotic-disorder-treatment-market

Hemorrhoids Treatment Device Market: https://www.factmr.com/report/577/hemorrhoids-treatment-device-market

Internal Boiler Treatment Chemicals Market: https://www.factmr.com/report/636/internal-boiler-treatment-chemicals-market

Mobile Water Treatment System Market: https://www.factmr.com/report/667/mobile-water-treatment-systems-market

Alexandrite Laser Treatment Market: https://www.factmr.com/report/870/alexandrite-gemstone-lasers-market

Pediatric HIV Infection Treatment Market: https://www.factmr.com/report/874/pediatric-hiv-infection-treatment-market

Perianal Infection Treatment Market: https://www.factmr.com/report/952/perianal-infection-treatment-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

This release was published on openPR.